What is WuXi Diagnostics?
WuXi Diagnostics, often referred to as WXDX, stands as a pioneering platform company in China, dedicated to the integrated diagnostics concept. Headquartered in Shanghai with an Independent Clinical Laboratory accredited by CAP, the company also operates an ISO13485-certified production facility in Suzhou and an R&D center at the Mayo Clinic headquarters in Rochester, US. By integrating Mayo Clinic's extensive knowledge and expertise in integrated medicine, WXDX is constructing an open-access enabling platform. This platform leverages multidisciplinary technologies, clinical big data, and advanced algorithms to consistently introduce innovative diagnostic services and products. Its mission is to empower healthcare innovators, accelerating technology transformation from research and development to practical application, thereby fostering a new ecosystem for next-generation diagnostics. WXDX excels in integrating medical and business resources, aiming to enhance healthcare practices and patient care through a 'license in + license out' model in collaboration with global partners.
How much funding has WuXi Diagnostics raised?
WuXi Diagnostics has raised a total of $150M across 1 funding round:
Series B
$150M
Series B (2021): $150M with participation from YF Capital, ABC International, Thermo Fisher Scientific, Sunland Capital, Shiyu Capital, and CCBI Tech Venture
Key Investors in WuXi Diagnostics
YF Capital
YF Capital is an investment firm that has participated in this funding round for WuXi Diagnostics.
ABC International
ABC International, accessible via www.abcintr.com, is a financial backer contributing to WuXi Diagnostics' strategic growth initiatives.
Thermo Fisher Scientific
Thermo Fisher Scientific, found at www.thermofisher.com, is a significant player in the life sciences industry and a key investor in WuXi Diagnostics' latest funding round.
What's next for WuXi Diagnostics?
The substantial enterprise-level funding and recent strategic investment signal a strong growth trajectory for WuXi Diagnostics. This capital infusion is expected to fuel further expansion of its integrated diagnostics platform, accelerate the development and commercialization of innovative diagnostic services and products, and strengthen its global partnerships. The company's focus on an open-access model and its strategic collaborations, particularly with institutions like the Mayo Clinic, position it for significant advancements in the rapidly evolving healthcare and medical technology sectors. WuXi Diagnostics is poised to continue its leadership in transforming diagnostic capabilities and improving patient outcomes.
See full WuXi Diagnostics company page
